Drug Profile
Research programme: dementia therapeutics - Autifony Therapeutics
Alternative Names: Voltage-gated ion channel therapeutics - Autifony TherapeuticsLatest Information Update: 24 Oct 2022
Price :
$50
*
At a glance
- Originator Autifony Therapeutics
- Class
- Mechanism of Action Voltage-gated potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Dementia
Most Recent Events
- 06 Oct 2022 Early research in Alzheimer's disease in United Kingdom (Autifony Therapeutics pipeline, October 2022)
- 06 Oct 2022 Autifony therapeutics is still conducting early research for Dementia in United Kingdom (Autifony Therapeutics pipeline, October 2022)
- 28 Apr 2021 No recent reports of development identified for research development in Dementia in United Kingdom